<DOC>
	<DOCNO>NCT00305188</DOCNO>
	<brief_summary>Primary Objective : Compare risk occurrence Grade3-4 cumulative peripheral sensory neuropathy ( PSN ) relative cumulative dose oxaliplatin treatment group placebo group . Main Secondary Objective : Compare response rate ( RR ) treatment group placebo group order ensure efficacy chemotherapy compromise addition xaliproden chemotherapeutic regimen . Other Secondary Objectives : study neurotoxicity parameter ( Duration oxaliplatin-induced PSN ( G2,3,4 ) ; overall incidence PSN treatment ; dose onset PSN ; incidence dose-reduction dose delay due PSN ; incidence oxaliplatin treatment discontinuation due PSN ; change Nerve Conduction Studies ( NCS ) ) ; study safety profile ( PSN ) ; study chemotherapy efficacy ( progression free survival , overall survival ) .</brief_summary>
	<brief_title>Evaluation Efficacy Xaliproden ( SR57746A ) Preventing Neurotoxicity Oxaliplatin / 5FU/LV Chemotherapy .</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Main inclusion criterion : Histologically cytologicallyproven metastatic cancer colon rectum . Metastatic disease amenable potentially curative treatment ( eg : inoperable metastatic disease ) . Male female age &gt; 18 year . WHO Performance Status ( PS ) : 0 1 . Measurable disease . No prior chemotherapeutic regimen metastatic disease . Diseasefree interval end adjuvant therapy least 6 month ( 1 year oxaliplatin part adjuvant therapy ) . Prior radiotherapy permit administered target lesion identify study unless progression within radiation portal document provide complete least 3 week randomization . Signed write informed consent prior study entry . Main exclusion criterion : Any condition past medical history contraindicates treatment oxaliplatin 5FU , report approved labeling information . Received chemotherapeutic agent 5FU , LV , Levamisole , irinotecan , capecitabine , oxaliplatin part adjuvant therapy . Peripheral neuropathy &gt; Grade 1 . Concomitant treatment drugs/ingredients report potential activity prevent peripheral sensory neuropathy . Concurrent active cancer originate primary site colon rectum . Presence symptom suggest brain metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Neurotoxicity syndrome</keyword>
	<keyword>Paresthesia</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Xaliproden</keyword>
</DOC>